chlorproguanil
Chlorproguanil is an antimalarial drug. In the late 90s and early 2000s, it was studied under collaboration with the UNICEF/UNDP/World Bank Special Program for Research and Training on Tropical Diseases and GlaxoSmithKline. It was a potential alternative to the preexisting combination therapy of chloroquine and sulfadoxine/pyrimethamine, as malaria was showing drug resistance to this approach. It has been trialled in combination therapy with artesunate to treat haemolysis after malaria treatment, however its development was prematurely stopped because of safety concerns secondary to its associated risk of haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase deficiency. — Wikipedia
Clinical trial activity
15 trials · 28 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2003 (NCT00519467)
Timeline
Indications
Approved for
Mechanism of action
- Dihydrofolate reductaseINHIBITOR
Dihydrofolate reductase inhibitor
Chemistry & pharmacology
SMILES
CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1- Mol. weight
- 288.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaChlorproguanil ↗
- ChEMBLCHEMBL1213553 ↗
Also known as
- 1-(3,4-dichlorophenyl)-5-isopropylbiguanide
- chlorproguanil
- chlorproguanil
- chlorproguanil
- chlorproguanil
- chlorproguanil
- chlorproguanil
- chlorproguanil
- lapudrine
- mono-hcl of chlorproguanil
- unspecified hcl of chlorproguanil
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00393679 | Phase 3 | Jul 1, 2007 | Albert Schweitzer Hospital, Centre Muraz, East African Network for Monitoring Antimalarial Treatment, Government of Mozambique, Government of Rwanda, Institute of Tropical Medicine, Belgium, Mbarara University of Science and Technology, Tropical Diseases Research Centre, Zambia, Uganda Malaria Surveillance Project, University of Antwerp, University of Barcelona, University of Calabar, University of Liverpool, University of Tuebingen |
| NCT00361114 | Phase 3 | Jul 1, 2006 | Kilimanjaro Christian Medical College, Tanzania, National Institute for Medical Research, Tanzania, University of London |
| NCT00344006 | Phase 3 | Jun 1, 2006 | GlaxoSmithKline |
| NCT00371735 | Phase 3 | Apr 1, 2006 | GlaxoSmithKline |
| NCT00126971 | Phase 1 | Jul 1, 2005 | Centers for Disease Control and Prevention (CDC), Malaria Research and Training Center, Bamako, Mali, University of Liverpool |
| NCT00119145 | Phase 4 | Jun 1, 2005 | Kintampo Health Research Centre, Ghana, University of London |
| NCT00164359 | Phase 4 | Apr 1, 2005 | Centers for Disease Control and Prevention (CDC), Government of Malawi |
| NCT00164710 | Phase 4 | Apr 1, 2005 | Centers for Disease Control and Prevention (CDC), Government of Malawi |
| NCT00461578 | N/A | Apr 1, 2005 | Institute of Tropical Medicine, Belgium, University of Antwerp, University of London |
| NCT00158574 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2005 | Kilimanjaro Christian Medical College, Tanzania, National Institute for Medical Research, Tanzania, University of Copenhagen, University of London |
| NCT00118794 | Phase 3 | Sep 1, 2004 | Medical Research Council, National Malaria Control Programme, The Gambia, University of London |
| NCT00111163 | N/A | Mar 1, 2004 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Kenya Medical Research Institute |
| NCT00158561 | Phase 3 | Feb 1, 2004 | HealthNet TPO, University of London |
| NCT00146731 | Phase 3 | Jan 1, 2004 | National Institute for Medical Research, Tanzania, University of London |
| NCT00519467 | Phase 2 | Jun 1, 2003 | GlaxoSmithKline |